<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2024000200005</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2024000200005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Protocolo de uso de omalizumab en urticaria crónica espontánea: desarrollo y datos de práctica clínica en vida real]]></article-title>
<article-title xml:lang="en"><![CDATA[Protocol for the use of omalizumab in chronic spontaneous urticaria: development and reallife clinical practice data]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Sierra]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ríos-Sánchez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Briceño-Casado]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Borrero-Rubio]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Armario-Hita]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Puerto Real Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Puerto Real Cádiz]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Sevilla Departamento de Farmacología Facultad de Farmacia]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario de Jerez Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Jerez de la Frontera Cádiz]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario de Puerto Real Servicio de Dermatología ]]></institution>
<addr-line><![CDATA[Puerto Real Cádiz]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>34</volume>
<numero>2</numero>
<fpage>119</fpage>
<lpage>123</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2024000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2024000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2024000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Describir el desarrollo e implementación de un protocolo de optimización de omalizumab en urticaria crónica espontánea, mostrando resultados en vida real.  Métodos: Estudio descriptivo retrospectivo de pacientes con urticaria crónica espontánea incluidos en el programa de optimización de omalizumab entre 01/10/2020-01/06/2021. La efectividad fue valorada mediante Urticaria Activity Score durante 7 días (UAS7), a los 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 meses. Se calcularon los pacientes respondedores (UAS7£15) y no respondedores (UAS7&gt;15), así como con buen control de la enfermedad (UAS7£6) y respuesta completa (UAS7=0). Se estimó el ahorro obtenido por la optimización mediante reducción de dosis o discontinuación por mejoría clínica.  Resultados: De los 47 pacientes incluidos, se había optimizado omalizumab en 29 (61,7%): 1 (2,1%) paciente presentó sólo reducción de dosis, 11 (23,4%) sólo discontinuación y 17 (36,2%) presentaron ambas. La mayoría de valoraciones de efectividad presentaron entre el 70-90% de respondedores. Sólo a los 12 meses se observó menor proporción de respondedores (66,7%). El ahorro económico total asociado a la optimización fue de 286.150,1 : 172.747,7 mediante discontinuación de tratamiento y 113.402,4 mediante reducción de dosis.  Conclusiones: El protocolo de optimización de omalizumab en urticaria crónica espontánea proporcionó una alta eficiencia, manteniendo una adecuada efectividad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objectives: To describe the development and implementation of an omalizumab optimisation protocol in chronic spontaneous urticaria, showing reallife data.  Methods: A retrospective descriptive study of patients with chronic spontaneous urticaria included in the omalizumab optimisation programme between 01/10/2020-01/06/2021 was conducted. Effectiveness was assessed by Urticaria Activity Score over 7 days (UAS7), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 months. Responders (UAS7£15) and non-responders (UAS7&gt;15), as well as patients with good disease control (UAS7£6) and complete response (UAS7=0) were estimated. Savings from optimisation by dose reduction or discontinuation due to clinical improvement were calculated.  Results: Forty-seven patients were included. Omalizumab was optimised in 29 patients (61.7%): 1 (2.1%) patient only presented dose reduction, 11 (23.4%) only treatment discontinuation and 17 (36.2%) had both interventions. Most effectiveness assessments presented between 70-90% of responders. Only the effectiveness valoration presented a lower proportion of responders (66.7%) at 12 months. The total economic savings associated with optimisation were 286,150.1 : 172,747.7 through treatment discontinuations and 113,402.4 through dose reductions.  Conclusions: The optimisation protocol for omalizumab in chronic spontaneous urticaria provided high efficiency, maintaining an adequate effectiveness.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="es"><![CDATA[protocolo]]></kwd>
<kwd lng="es"><![CDATA[urticaria crónica espontánea]]></kwd>
<kwd lng="es"><![CDATA[efectividad]]></kwd>
<kwd lng="es"><![CDATA[eficiencia]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[protocol]]></kwd>
<kwd lng="en"><![CDATA[chronic spontaneous urticaria]]></kwd>
<kwd lng="en"><![CDATA[effectiveness]]></kwd>
<kwd lng="en"><![CDATA[efficiency]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic spontaneous urticaria: etiology and pathogenesis]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2014</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bracken]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[MacLeod]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune theories of chronic spontaneous urticaria]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathias]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Crosby]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Rosén]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Zazzali]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2012</year>
<volume>108</volume>
<page-range>20-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha Técnica de Xolair® 150 mg]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosén]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grattan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gimenéz-Arnau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>924-35</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ledford]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ashby]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Canvin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zazzali]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2013</year>
<volume>132</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>101-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Bindslev-Jensen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grob]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baskan]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study]]></article-title>
<source><![CDATA[J Invest Dermatol]]></source>
<year>2015</year>
<volume>135</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-75</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsubara]]></surname>
<given-names><![CDATA[Daiki]]></given-names>
</name>
<name>
<surname><![CDATA[Takahagi]]></surname>
<given-names><![CDATA[Shunsuke]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[Ryo]]></given-names>
</name>
<name>
<surname><![CDATA[Kamegashira]]></surname>
<given-names><![CDATA[Akiko]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Akio]]></given-names>
</name>
<name>
<surname><![CDATA[Hide]]></surname>
<given-names><![CDATA[Michihiro]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria]]></article-title>
<source><![CDATA[J Dermatol]]></source>
<year>2021</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Thilakanathan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Xuan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mohsen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings]]></article-title>
<source><![CDATA[Intern Med J]]></source>
<year>2021</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>739-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuberbier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aberer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Asero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bindslev-Jensen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Church]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EAACI/GA2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2014</year>
<volume>69</volume>
<page-range>868-87</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stull]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McBride]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gimenez Arnau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marsland]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2017</year>
<volume>177</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1093-101</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uysal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Eller]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mortz]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Bindslev-Jensen]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2014</year>
<volume>133</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>914.e2-5.e2</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spertino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Curto Barredo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rozas Muñoz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras Nart]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gimenez Arnau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serra Baldrich]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Algorithm for treatment of chronic spontaneous urticaria with omalizumab]]></article-title>
<source><![CDATA[Actas Dermosifiliogr (Engl Ed)]]></source>
<year>2018</year>
<volume>109</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>771-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giménez Arnau]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Valero Santiago]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bartra Tomás]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jáuregui Presa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Labrador Horrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miquel Miquel]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2019</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>338-48</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arcaya]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Arcaya]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Subramanian]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inequalities in health: definitions, concepts, and theories]]></article-title>
<source><![CDATA[Glob Health Action]]></source>
<year>2015</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ohanyan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Church]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis]]></article-title>
<source><![CDATA[J Dermatol Sci]]></source>
<year>2013</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-62</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sussman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hébert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barron]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bian]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Caron-Guay]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Laflamme]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reallife experiences with omalizumab for the treatment of chronic urticaria]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2014</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>170-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
